Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Gold compounds with anti-HIV and immunomodulatory activity
Thesis (PhD)--University of Pretoria, 2011.
Saved in:
| Other Authors: | |
|---|---|
| Format: | Thesis |
| Published: |
University of Pretoria
2013
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613704894283776 |
|---|---|
| access_status_str | Open Access |
| author2 | Meyer, Debra |
| author_browse | Meyer, Debra |
| author_facet | Meyer, Debra |
| collection | Thesis |
| dc_rights_str_mv | © 2011 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. |
| description | Thesis (PhD)--University of Pretoria, 2011. |
| format | Thesis |
| id | oai:repository.up.ac.za:2263/24951 |
| institution | University of Pretoria (South Africa) |
| last_indexed | 2026-06-10T12:40:23.116Z |
| license_str | Other — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UPSpace — University of Pretoria Institutional Repository |
| publishDate | 2013 |
| publishDateRange | 2013 |
| publishDateSort | 2013 |
| publisher | University of Pretoria |
| publisherStr | University of Pretoria |
| record_format | dspace |
| source_str | UPSpace — University of Pretoria Institutional Repository |
| spelling | oai:repository.up.ac.za:2263/24951 Gold compounds with anti-HIV and immunomodulatory activity Meyer, Debra s28594267@tuks.co.za Fonteh, Pascaline Nanga Human immunodeficiency virus (HIV) Acquired immune deficiency syndrome (AIDS) Viral life cycle Gold compounds UCTD Thesis (PhD)--University of Pretoria, 2011. The human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) that subsequently develops remain major health concerns even after three decades since the first cases were reported. Successful therapeutic measures to address HIV/AIDS consist mostly of combinations of drugs targeting viral enzymes including reverse transcriptase (RT), protease (PR) and integrase (IN) as well as entry steps of the viral life cycle. The remarkable benefits (e.g. improved quality of life) derived from the use of these agents are unfortunately limited by toxicity to the host and the development of drug resistant viral strains. Drug resistance limits the repertoire of drug combinations available. Unfortunately, because latent forms of the virus exists, therapy has to be life-long and with new infections occurring every day, resistant strains tend to spread. To circumvent these problems, new drugs that inhibit resistant strains or work against new viral targets have to be developed. The history of gold compounds as potential inhibitors of HIV prompted this study in which twenty seven compounds consisting of gold(I), gold(III) and precursors from five classes were tested for drug-likeness, anti-HIV and immunomodulatory effects using wet lab and in silico methodologies. Cytotoxicity determination was done using viability dyes and flow cytometry. Cell proliferation profiles were monitored using the carboxyflourescein succinimidyl ester dye dilution technology and a real time cell analyser for confirming viability dye findings. The compounds’ effects on viral enzymes was determined using direct enzyme assays and in silico molecular modelling techniques. H and P nuclear magnetic resonance spectroscopy studies for determining stability revealed that the backbone chemical shifts of the compounds were relatively unchanged after one week (-20 and 37 ºC) when dissolved in dimethylsulfoxide. Eight of the gold compounds had drug-like properties comparable to clinically available drugs when in silico predictions were performed. The 50% cytotoxic dose of the compounds in human cells was between 1 and 20 μM (clinically relevant concentrations for gold compounds). Three gold(I) compounds inhibited viral infectivity at non-toxic concentrations and two gold(III) compounds did so at cytostatic (anti-proliferative mechanism that is also antiviral) concentrations. In the immunomodulatory assay, cytokine levels were altered by five compounds with one gold(I) and a gold(III) compound significantly reducing the frequency of CD4+ cells (an anti-viral function) from HIV+ donors (p= 0.005 and 0.027 respectively) when multi-parametric flow cytometry was performed. Inhibition of RT activity was predicted in in silico studies to be through interactions with the ribonuclease (RNase) H site although with poor stereochemical orientation while favourable binding predictions with the IN cofactor binding site were observed for some gold(III) complexes. Compounds predicted to interact with the RNase H site of RT and the IN cofactor site require structural modification to improve drug-likeness and binding affinity. The drug-like compound(s) which inhibited viral infectivity and lowered CD4+ cell frequency have potential for incorporation into virostatic cocktails (combination of cytostatic and directly anti-viral agent). Cytostatic agents are known to be less prone to drug resistance and because they lower CD4+ cell frequency, such compounds can potentially limit HIV immune activation. Biochemistry unrestricted 2013-09-06T18:55:35Z 2012-06-07 2013-09-06T18:55:35Z 2012-04-19 2011 2012-05-24 Thesis Fonteh, PN 2011, Gold compounds with anti-HIV and immunomodulatory activity, PhD thesis, University of Pretoria, Pretoria, viewed yymmdd < http://hdl.handle.net/2263/24951 > D12/4/445/ag http://hdl.handle.net/2263/24951 http://upetd.up.ac.za/thesis/available/etd-05242012-155038/ © 2011 University of Pretoria. All rights reserved. The copyright in this work vests in the University of Pretoria. No part of this work may be reproduced or transmitted in any form or by any means, without the prior written permission of the University of Pretoria. application/pdf application/pdf application/pdf application/pdf application/pdf application/pdf application/pdf application/pdf University of Pretoria |
| spellingShingle | Human immunodeficiency virus (HIV) Acquired immune deficiency syndrome (AIDS) Viral life cycle Gold compounds UCTD Gold compounds with anti-HIV and immunomodulatory activity |
| title | Gold compounds with anti-HIV and immunomodulatory activity |
| title_full | Gold compounds with anti-HIV and immunomodulatory activity |
| title_fullStr | Gold compounds with anti-HIV and immunomodulatory activity |
| title_full_unstemmed | Gold compounds with anti-HIV and immunomodulatory activity |
| title_short | Gold compounds with anti-HIV and immunomodulatory activity |
| title_sort | gold compounds with anti hiv and immunomodulatory activity |
| topic | Human immunodeficiency virus (HIV) Acquired immune deficiency syndrome (AIDS) Viral life cycle Gold compounds UCTD |
| url | http://hdl.handle.net/2263/24951 http://upetd.up.ac.za/thesis/available/etd-05242012-155038/ |